Amended Current Report Filing (8-k/a)
March 05 2021 - 4:55PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K/A
CURRENT REPORT
(Amendment No. 1)
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
March 5, 2021 (February 8, 2021)
PETRA ACQUISITION, INC.
(Exact Name of Registrant as Specified in Charter)
Delaware
|
|
001-39603
|
|
84-3898466
|
(State or Other Jurisdiction
|
|
(Commission
|
|
(IRS Employer
|
of Incorporation)
|
|
File Number)
|
|
Identification No.)
|
5 West 21st Street New York,
NY 10010
(Address of Principal Executive Offices) (Zip
Code)
(971) 622-5800
(Registrant’s Telephone Number, Including
Area Code)
Not Applicable
(Former Name or Former Address, if Changed Since
Last Report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c))
|
Securities registered
pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange on
which registered
|
Units, each consisting of one share of common stock and one redeemable warrant
|
|
PAICU
|
|
The Nasdaq Stock Market LLC
|
Common stock, par value $0.001 per share
|
|
PAIC
|
|
The Nasdaq Stock Market LLC
|
Redeemable warrants, exercisable for shares of common stock at an exercise price of $11.50 per share
|
|
PAICW
|
|
The Nasdaq Stock Market LLC
|
Indicate by check mark
whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Explanatory Note
This Amendment No. 1 to the Current
Report on Form 8-K amends Item 5.02 of the Current Report on Form 8-K filed on February 23, 2021 (the “Original
Form 8-K”) solely to correct an error on the date of resignation of Mr. Angelides. Except
to the extent expressly set forth herein, this amended Form 8-K speaks as of the filing date of the Original Form 8-K and has not
been updated to reflect events occurring subsequent to the original filing date. Accordingly, this amended Form 8-K should be read
in conjunction with our filings made with the Securities and Exchange Commission subsequent to the filing of the Original Form
8-K, as applicable.
Item 5.02 Departure of Directors
or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On February 8, 2021, Kimon
Angelides (“Mr. Angelides”) resigned as a member of the Board of Directors (the “Board”) of Petra Acquisition,
Inc. (the “Company”). To fill the vacancy on the Audit Committee of the Board (the “Committee”) created
by Mr. Angelides’ resignation, the Board appointed Anthony Hayes, a current independent Board member, to serve as a member
of the Committee.
Effective February 22, 2021, the corporate
governance and nominating committee recommended, and the board of directors approved, the appointment of William H. Carson to fill
the vacancy resulting from the resignation of Mr. Angelides. The Board determined that Mr. Carson qualifies as independent under
the director independence standards set forth in the rules and regulations of the Securities and Exchange Commission and applicable
NASDAQ listing standards.
There is no arrangement or understanding between Mr. Carson and
any other persons pursuant to which Mr. Carson was selected as a director, and there are no related party transactions involving
Mr. Carson that are reportable under Item 404(a) of Regulation S-K. Mr. Carson will receive ten thousand (10,000) shares of the
Company’s common stock from the Company’s Sponsor, Petra Investment Holdings, LLC, as compensation for his service
on the Board.
Below is a description of Mr. Carson’s professional
work experience.
William H. Carson,
73, of Texas, is a forty year management veteran in the prescription and OTC drug industries with broad exposure to product licensing,
new product R&D, manufacturing, Rx-to-OTC switches, company acquisition and new business entity development. He has held Leadership
roles at Novartis, Bayer, Galderma, in MTO (Plant Management, New Facility Construction, Compliance), Product Development and Regulatory
Affairs (NDA, ANDA, RX to OTC Switch, OTC Monographs), and LMA (Due Diligence, Organizational Review, Post Merger/Acquisition Integration).
For the past 9 years,
Carson has operated his own consulting business taking on consulting assignments in: compliance, production, licensing and acquisition
product development and FDA/regulatory strategy. Carson started his career with Dorsey Laboratories Division, Sandoz Pharmaceuticals
where he remained employed from 1972-1994 ; he served in a variety of director roles such as Director of Regulatory Affairs, and
Director of New Products. He last served as Vice President of Scientific Affairs, managing the the FDA approval process for the
switches of Tavist-1 and Tavist-D from Rx to OTC status. From 1994-1996, he served as Senior Vice President of OTC Products at
Goldline Pharmaecuticals. From 1996-2004 he was Vice President, Scientific Affairs with Bayer Consumer Care Division (NYSE: BAYRY).
From 1996- 2004 he served as Senior Vice-President, Medical &Regulatory Affairs at Galderma Laboratories, a skin health pharma
company. There he built departments to support a period of rapid sales growth, new product approvals and acquisitions. He also
was the team leader for the integration of two major acquisitions, Collagenix in the U.S. and Q-Med in Europe.
Mr. Carson has a BS and MS from University
of Nebraska in Physiology and Biochemistry.
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
Dated: March 5, 2021
|
PETRA ACQUISITION, INC.
|
|
|
|
|
By:
|
/s/ Andreas Typaldos
|
|
Name:
|
Andreas Typaldos
|
|
Title:
|
Chairman & Chief Executive Officer
|
Petra Acquisition (NASDAQ:PAIC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Petra Acquisition (NASDAQ:PAIC)
Historical Stock Chart
From Apr 2023 to Apr 2024